Trodelvy (sacituzumab govitecan-hziy) vs Margenza (margetuximab-cmkb)
Trodelvy (sacituzumab govitecan-hziy) vs Margenza (margetuximab-cmkb)
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate specifically indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It works by targeting the Trop-2 receptor, which is commonly expressed in many types of epithelial cancers, including breast cancer, and delivering a potent chemotherapy drug directly to the cancer cells. On the other hand, Margenza (margetuximab-cmkb) is a monoclonal antibody designed to target HER2-positive breast cancer, approved for use in combination with chemotherapy for the treatment of patients who have previously received two or more anti-HER2 regimens; it is engineered to increase the immune system's attack on cancer cells. The choice between these two medications would depend on the specific characteristics of the patient's breast cancer, particularly the expression of the Trop-2 receptor and HER2 status, as well as their prior treatment history. Patients are advised to consult with their oncologist to determine which medication is most appropriate for their individual condition.
Difference between Trodelvy and Margenza
Metric | Trodelvy (sacituzumab govitecan-hziy) | Margenza (margetuximab-cmkb) |
---|---|---|
Generic name | Sacituzumab govitecan | Margetuximab |
Indications | Metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer | Metastatic HER2-positive breast cancer |
Mechanism of action | Antibody-drug conjugate targeting Trop-2 | Anti-HER2 monoclonal antibody |
Brand names | Trodelvy | Margenza |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash, and abdominal pain | Fatigue, nausea, diarrhea, vomiting, constipation, headache, fever, joint pain, extremity pain, increased cough, dyspnea, decreased appetite |
Contraindications | Severe hypersensitivity to sacituzumab govitecan-hziy | Severe hypersensitivity to margetuximab-cmkb or any of its excipients |
Drug class | Antibody-drug conjugate | Monoclonal antibody |
Manufacturer | Immunomedics, Inc. | MacroGenics, Inc. |
Efficacy
Trodelvy (sacituzumab govitecan-hziy) Efficacy in Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate specifically indicated for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. The efficacy of Trodelvy was evaluated in a study known as IMMU-132-01, a multicenter, single-arm trial. Patients treated with Trodelvy showed a significant improvement in overall response rate (ORR), with a percentage of patients experiencing partial or complete shrinkage of their tumors. Additionally, the median duration of response (DoR) was notable, suggesting that the responses to Trodelvy can be durable.
Further supporting its efficacy, Trodelvy has demonstrated a clinically meaningful improvement in overall survival (OS) in patients with metastatic TNBC. In a phase III trial, ASCENT, patients treated with Trodelvy had a statistically significant and clinically meaningful improvement in OS compared to those receiving standard chemotherapy. These results underscore Trodelvy's potential as a valuable treatment option for patients with this aggressive form of breast cancer.
Margenza (margetuximab-cmkb) Efficacy in Breast Cancer
Margenza (margetuximab-cmkb), in combination with chemotherapy, is approved for the treatment of patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease. The approval of Margenza was based on the results of the SOPHIA study, a phase III clinical trial. In this study, patients receiving Margenza in combination with chemotherapy showed an improvement in progression-free survival (PFS) compared to those receiving trastuzumab and chemotherapy. The ORR also favored the Margenza combination, indicating that a higher proportion of patients experienced tumor shrinkage.
While the SOPHIA study demonstrated a trend toward improved OS with Margenza, this result did not reach statistical significance at the time of the primary analysis. However, the improvement in PFS and ORR suggests that Margenza, when used in combination with chemotherapy, can be an effective treatment option for patients with previously treated HER2-positive metastatic breast cancer. Ongoing studies and additional follow-up may provide further insights into the long-term benefits of Margenza in this patient population.
Regulatory Agency Approvals
Trodelvy
Margenza
Access Trodelvy or Margenza today
If Trodelvy or Margenza are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us